Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (Currently Amended) ~~Pharmaceutical~~ A pharmaceutical composition~~, characterised in that it contains one or more~~ comprising at least one anticholinergic,[[s]] [[(1)]] in combination with ~~one or more anti-TNF antibodies (2)~~ at least one anti-TNF antibody, wherein at least one of at least one anticholinergic and the at least one anti-TNF antibody is optionally in the form of ~~the~~ individual optical isomers, mixtures ~~thereof~~ or racemates thereof, ~~and~~ is optionally in the form of ~~the~~ pharmacologically acceptable acid addition salts thereof, and is optionally in the form of ~~the~~ solvates or hydrates ~~and optionally together with a pharmaceutically acceptable excipient~~.

2. (Currently Amended) ~~Pharmaceutical~~ The pharmaceutical composition according to claim 1, ~~characterised in that 1~~ wherein at least one anticholinergic of the composition is selected from ~~among the~~ the group consisting of tiotropium salts, oxitropium salts, [[or]] and ipratropium salts~~, preferably tiotropium salts~~.

3. (Currently Amended) ~~Pharmaceutical~~ The pharmaceutical composition according to claim 2, ~~characterised in that 1 is present in the form of the~~ wherein at least one anticholinergic in the composition comprises at least one of a chloride, bromide, iodide, methanesulphonate, [[or]] and para-toluenesulphonate~~, preferably in the form of the bromide~~.

4. (Currently Amended) ~~Pharmaceutical~~ The pharmaceutical composition according to ~~one of claims 1 to 3~~ claim 1, wherein the at least one anti-TNF antibody ~~2 can be~~ is at least one of polyclonal, [[or]] monoclonal, ~~can be~~ modified by pegylation ~~or can be~~ and a fragment of an antibody ~~(which may or may not be fused to another protein), as long the fragment~~ that contains at least one high affinity TNF alpha binding site.

5. (Currently Amended) ~~Pharmaceutical~~ The pharmaceutical composition according to claim 4, ~~characterised in that 2 selected from among~~ wherein the at least one anti-TNF antibody is at least one of infliximab, adalimumab, afelimomab, CDP-571 ~~(trade name Humicade)~~ and CDP-870.

6. (Currently Amended) ~~Pharmaceutical~~ The pharmaceutical composition according to claim 4, ~~or 5, characterised in that 2 is seleceted from among~~ wherein the at least one anti-TNF antibody is at least one of CDP-571 [[or]] and infliximab.

7. (Currently Amended) ~~Pharmaceutical~~ The pharmaceutical composition according to ~~one of claims 1 to 6, characterised in that the active substances 1 and 2~~ claim 1, wherein the at least one anticholinergic and the at least one anti-TNF antibody are present in the composition either together in a single formulation or in two separate formulations.

8. (Currently Amended) ~~Pharmaceutical~~ The pharmaceutical composition according to ~~one of claims 1 to 7, characterised in that~~ claim 1, wherein the weight ratios of ~~1 to 2~~ the at least one anticholinergic and the at least one anti-TNF antibody are in the range from 1:2000 to 1:1~~, preferably from 1:1000 to 1:5~~.

9. (Currently Amended) ~~Pharmaceutical composition according to one of claims 1 to 8, characterised in that a single administration corresponds to a dose of the active substance combination 1 and 2 of 1 to 10000µg, preferably from 10 to 5000µg~~ A method of administering a pharmaceutical composition comprising:

providing a pharmaceutical composition according to claim 1; and

administering the pharmaceutical composition at a selected dosage such that the at least one anticholinergic and the at least one anti-TNF antibody in the administered composition is in the range from 1 µg to 10000µg.

10. (Currently Amended) ~~Pharmaceutical~~ The pharmaceutical composition according to ~~one of claims 1 to 9, characterised in that it is in the form of~~ claim 1, wherein the composition is a formulation suitable for inhalation.

11. (Currently Amended) ~~Pharmaceutical~~ The pharmaceutical composition according to claim 10, ~~characterised in that it~~ wherein the composition is a formulation selected from ~~among~~ the group consisting of inhalable powders, ~~and~~ inhalable solutions, ~~or~~ and suspensions.

12. (Currently Amended) ~~Pharmaceutical~~ The pharmaceutical composition according to claim 11, ~~characterised in that it is~~ wherein the composition is an inhalable powder which contains ~~1 and 2~~ the at least one anticholinergic and the at least one anti-TNF antibody in admixture with ~~suitable~~ at least one physiologically acceptable excipient[[s]] selected from ~~among~~ the group consisting of monosaccharides, disaccharides, oligo[[-]]saccharides, and polysaccharides, polyalcohols, salts, ~~or mixtures of these excipients with one another~~ and mixtures thereof.

13. (Currently Amended) ~~Inhalable~~ An inhalable powder comprising the pharmaceutical composition according to claim 12, ~~characterised in that the~~ wherein the at least one physiologically acceptable excipient has a maximum mass mean aerodynamic diameter of up to 250μm~~, preferably between 10 and 150μm~~.

14. (Currently Amended) ~~Capsules, characterised in that they contain~~ A capsule containing an inhalable powder according to claim 12 ~~or 13~~.

15. (Currently Amended) ~~Pharmaceutical~~ The pharmaceutical composition according to claim 11, ~~characterised in that it~~ wherein the composition is an inhalable powder which contains only the ~~active substances 1 and 2 as its ingredients~~ at least one anticholinergic and the at least one anti-TNF antibody.

16. (Currently Amended) ~~Pharmaceutical~~ The pharmaceutical composition according to claim 11, ~~characterised in that it~~ wherein the composition is [[a]] an inhalable solution or suspension which contains a solvent comprising one of water, ethanol or a mixture of water and ethanol ~~as solvent~~.

17. (Currently Amended) ~~Inhalable~~ An inhalable solution or suspension comprising the pharmaceutical composition according to claim 16, ~~characterised in that~~ wherein the pH of the inhalable solution or suspension is from 2-7~~, preferably 2-5~~.

18. (Currently Amended) ~~Use of a capsule according to claim 14 in an inhaler, preferably in a Handihaler.~~ A method of providing a dosage of an inhalable powder comprising:

providing a capsule containing an inhalable powder according to claim 11; and

administering a dosage of the inhalable powder in the capsule using an inhaler.

19. (Currently Amended) ~~Use of an inhalable solution according to one of claims 15 or 16 for nebulising in an inhaler according to WO 91/14468 or an inhaler as described in Figures 6a and 6b of WO 97/12687.~~ A method of providing a dosage of an inhalable solution comprising:

providing an inhalable solution comprising a pharmaceutical composition according to claim 11 and a solvent comprising one of water, ethanol or a mixture of water and ethanol; and

administering a dosage of the inhalable solution by nebulizing the inhalable solution in an inhaler.

20. (Currently Amended) ~~Use of a composition according to one of claims 1 to 17 for preparing a medicament for treating inflammatory or obstructive diseases of the respiratory tract.~~ A method of preparing a medicament for treating inflammatory or obstructive diseases of the respiratory tract, the method comprising providing a pharmaceutical composition according to claim 1.

21. (New) The pharmaceutical composition of claim 1, further comprising a pharmaceutically acceptable excipient.

22. (New) The pharmaceutical composition according to claim 1, wherein the weight ratios of the at least one anticholinergic and the at least one anti-TNF antibody are in the range from 1:1000 to 1:5.

23. (New) The method of claim 9, wherein the pharmaceutical composition is administered at a selected dosage such that the at least one anticholinergic and the at least one anti-TNF antibody in the administered composition is in the range from 10 μg to 5000μg.

24. (New) The inhalable powder according to claim 13, wherein the at least one physiologically acceptable excipient has a maximum mass mean aerodynamic diameter of between 10 and 150μm.

25. (New) The inhalable solution or suspension of claim 17, wherein the pH of the inhalable solution or suspension is from 2-5.